<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0065">
 <label>13</label>
 <element-citation publication-type="journal" id="h0065">
  <person-group person-group-type="author">
   <name>
    <surname>Van Der Meeren</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Hatherill</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nduba</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Wilkinson</surname>
    <given-names>R.J.</given-names>
   </name>
   <name>
    <surname>Muyoyeta</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Van Brakel</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis</article-title>
  <source>N Engl J Med</source>
  <volume>379</volume>
  <year>2018</year>
  <fpage>1621</fpage>
  <lpage>1634</lpage>
  <pub-id pub-id-type="pmid">30280651</pub-id>
 </element-citation>
</ref>
